SUVEN
Suven
Live Price
₹258.85
-5.35-2.02%
Conviction Scorecard
AI Momentum
43%Technical Rating
30%Analyst Sentiment
85%Market News & Buzz
📰
Recent news and updates for SUVEN will appear here soon.
Stockmo Analyst Rationale
AI Generated Insight
"Balanced market signals for SUVEN. The stock is currently consolidating with neutral technical indicators and fundamental alignment between current healthcare growth rates and prevailing valuation metrics."
Verified by Stockmo Intelligence Grid
Supporting Evidence
Citing cross-referenced internal documents and market technicals
About Suven
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Frequently asked questions
As of the latest market session, Suven (SUVEN) is trading at ₹258.85, representing a move of -2.02% from the previous close.
Suven is listed and traded under the ticker symbol SUVEN on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Suven's stock price moved by -2.02%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 43% bullish probability for SUVEN stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Suven shares reached a high of ₹403.35 and hit a low of ₹124.11.
SUVEN exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 2,27,678 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Suven has a market capitalization of ₹7314.14 Cr, designating its size class inside the Healthcare sector.
Suven has a current dividend yield of N/A. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Suven's trailing Price-to-Earnings (P/E) ratio is —. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Suven (SUVEN) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Suven's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore SUVEN's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for SUVEN are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Suven operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.